Literature DB >> 31456556

Trends and inequities in amenable mortality between 1997 and 2012 in South Africa.

I Neethling1, P Groenewald, H Schneider, D Bradshaw.   

Abstract

BACKGROUND: Amenable mortality comprises causes of death that should not occur with timely and effective healthcare. It is commonly used to assess healthcare performance. It could also be used to assess the effectiveness of the pending National Health Insurance (NHI) in South Africa (SA), but to do this, the level and distribution of amenable mortality are required using a local list of amenable causes.
OBJECTIVES: To establish an amenable cause-of-death list appropriate for SA and to determine the levels, trends, geographical distribution, population group differences and international comparisons of mortality amenable to healthcare.
METHODS: A local list of amenable causes of death was developed with input from public health and disease-specific medical experts. The Second SA National Burden of Disease estimates were reclassified into amenable mortality. Analyses of age-standardised death rates (ASDRs) and amenable mortality proportions were conducted by province and population group between 1997 and 2012. Excess mortality in relation to the best- performing province and population group was also analysed. ASDRs for SA were compared with those of European Union (EU) and Organisation for Economic Co-operation and Development (OECD) countries.
RESULTS: The local list of amenable conditions contained 45 causes of death. There were large disparities in amenable mortality between provinces and population groups, which did not attenuate over time. There was an average annual percentage increase in amenable ASDRs, but when HIV/AIDS was excluded from the analysis there was an average annual decrease of 1.12%. In the post-peak HIV/AIDS period between 2008 and 2012, an annual average of 207 810 amenable deaths could have been saved if all provinces had the same ASDR as the Western Cape. SA's ASDR was 2.6 and 2.2 times higher than that of the worst-performing EU and OECD country, respectively.
CONCLUSIONS: This is the first study known to the authors that has established a local amenable mortality list and described the epidemiology of amenable mortality in SA. Amenable mortality could be used as an indicator of the performance of the pending NHI over time and, in combination with other indicators, could identify areas of the health system that require improvement. Benchmarking could also quantify gaps in health system performance between geographical regions and indicate whether these are reduced with time.

Entities:  

Year:  2019        PMID: 31456556     DOI: 10.7196/SAMJ.2019.v109i8.13796

Source DB:  PubMed          Journal:  S Afr Med J


  4 in total

1.  Integrating gestational diabetes and type 2 diabetes care into primary health care: Lessons from prevention of mother-to-child transmission of HIV in South Africa - A mixed methods study.

Authors:  Jean Claude Mutabazi; Pascal Roland Enok Bonong; Helen Trottier; Lisa Jayne Ware; Shane A Norris; Katherine Murphy; Naomi Levitt; Christina Zarowsky
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

2.  Examining the Economic Perspective of Treatable Mortality: The Role of Health Care Financing and the Importance for Economic Prosperity.

Authors:  Viera Ivankova; Beata Gavurova; Samer Khouri; Gabriel Szabo
Journal:  Front Public Health       Date:  2021-12-13

3.  Refining circumstances of mortality categories (COMCAT): a verbal autopsy model connecting circumstances of deaths with outcomes for public health decision-making.

Authors:  Lucia D'Ambruoso; Jessica Price; Eilidh Cowan; Gerhard Goosen; Edward Fottrell; Kobus Herbst; Maria van der Merwe; Jerry Sigudla; Justine Davies; Kathleen Kahn
Journal:  Glob Health Action       Date:  2021-10-26       Impact factor: 2.640

4.  Burden of mortality linked to community-nominated priorities in rural South Africa.

Authors:  Pyry Mattila; Justine Davies; Denny Mabetha; Stephen Tollman; Lucia D'Ambruoso
Journal:  Glob Health Action       Date:  2022-12-31       Impact factor: 2.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.